Search for: "Long v. Mylan Inc. et al"
Results 1 - 15
of 15
Sorted by Relevance
|
Sort by Date
3 Oct 2022, 8:27 am
Filler, et al. v. [read post]
15 Jun 2007, 8:11 am
Mylan Laboratories, Inc., et al., and Ormco Corporation, et al. v. [read post]
5 May 2010, 4:46 am
Mylan Pharmaceuticals Inc. et al. [read post]
3 Feb 2016, 8:57 am
Apotex Inc., No. 15-281 Mylan Pharmaceuticals Inc. v. [read post]
13 Oct 2016, 6:50 am
Lee, No. 16-446 (Eligibility of new use of old manufacture – blackjack game) Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
1 Apr 2016, 8:22 am
Cordis Corporation, et al., No. 15-998 Laches: SCA Hygiene Products Aktiebolag, et al. v. [read post]
3 May 2016, 1:42 am
Apple Inc., No 15-777 (design patent damages calculation) Stryker Corporation, et al. v. [read post]
7 Sep 2011, 4:22 am
Highlights this week included: US: CAFC: Immunisation methods are patent eligible: Classen Immunotherapies, Inc v Biogen IDEC et al (Inventive Step) (Orange Book Blog) (Patently-O) (Patent Docs) (Patent Docs) (IPBiz) (Patent Law Practice Center) (Patent Baristas) US: FTC issues long-awaited final report on authorized generics; report examines both the short-term effects and long-term impact on competition and drug prices (FDA Law Blog)… [read post]
29 Jul 2013, 12:16 pm
Cephalon Inc. et al. v. [read post]
18 Apr 2012, 1:29 pm
Janssen Pharmaceuticals, Inc., 951 N.E.2d 1238 (Ill. [read post]
27 May 2011, 8:56 am
Amicus brief of Altera Corporation et al.CVSG Information:Invited: December 13, 2010Filed: May 17, 2011 (Deny) Title: Extreme Networks, Inc. v. [read post]
9 Aug 2012, 5:00 am
Bard, Inc. [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South… [read post]
17 Mar 2020, 1:32 pm
For instance, when evaluating a company’s medical device recall strategy, the FDA considers several factors, including (but not limited to): Results of a health hazard evaluation assessing the extent of any harm done, to whom, for how long. [read post]
13 Jun 2008, 3:40 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ECJ rules trade mark holders cannot stop honest comparative advertising: O2 Holdings Limited and O2 (UK) Limited v Hutchinson 3G UK Limited: (Out-Law), (Catch Us If You Can!!!) [read post]
